Tianjin Lisheng Pharmaceutical Co.,Ltd.

XSEC:002393 주식 보고서

시가총액: CN¥4.4b

Tianjin Lisheng PharmaceuticalLtd 과거 수익 실적

과거 기준 확인 2/6

Tianjin Lisheng PharmaceuticalLtd has been growing earnings at an average annual rate of 22.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 4.8% per year. Tianjin Lisheng PharmaceuticalLtd's return on equity is 3.7%, and it has net margins of 14.9%.

주요 정보

22.3%

수익 성장률

22.2%

EPS 성장률

Pharmaceuticals 산업 성장10.9%
매출 성장률-4.8%
자기자본 수익률3.7%
순이익14.9%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Tianjin Lisheng PharmaceuticalLtd 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

XSEC:002393 수익, 비용 및 수입 (CNY Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 241,265188453119
30 Jun 241,24037444891
31 Mar 241,182374425103
31 Dec 231,153362429102
30 Sep 231,15632444191
30 Jun 231,189112466103
31 Mar 231,17698467100
01 Jan 231,14794449102
30 Sep 221,158137481111
30 Jun 221,119133469107
31 Mar 221,071128450101
01 Jan 221,092122466101
30 Sep 211,0612744894
30 Jun 211,1141348293
31 Mar 211,1361051078
31 Dec 201,141954773
30 Sep 201,32113364382
30 Jun 201,37415668690
31 Mar 201,513178773102
31 Dec 191,615188813120
30 Sep 191,61321583975
30 Jun 191,58920583874
31 Mar 191,54418879887
31 Dec 181,50418576992
30 Sep 181,366122707129
30 Jun 181,273107564188
31 Mar 181,138117479144
01 Jan 181,029117420101
30 Sep 1797513734885
30 Jun 179151253940
31 Mar 178961143860
31 Dec 168471163500
30 Sep 16792743270
30 Jun 16769773040
31 Mar 167791102950
31 Dec 157751142910
30 Sep 157621043010
30 Jun 157591043070
31 Mar 15725753010
31 Dec 14774933230
30 Sep 148511293370
30 Jun 149251783450
31 Mar 141,0162523650
31 Dec 131,0442933510

양질의 수익: 002393 has high quality earnings.

이익 마진 증가: 002393's current net profit margins (14.9%) are lower than last year (28%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: 002393's earnings have grown significantly by 22.3% per year over the past 5 years.

성장 가속화: 002393's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

수익 대 산업: 002393 had negative earnings growth (-41.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).


자기자본 수익률

높은 ROE: 002393's Return on Equity (3.7%) is considered low.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기